Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02117362
Recruitment Status : Completed
First Posted : April 17, 2014
Last Update Posted : March 21, 2019
Providence Cancer Center, Earle A. Chiles Research Institute
Galectin Therapeutics Inc.
Information provided by (Responsible Party):
Providence Health & Services

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : November 28, 2018
Actual Study Completion Date : November 28, 2018